Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.39 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.39 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.39 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.39 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.39 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.39 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.39 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.39 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 5/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358285 | 0.82 | DRD2 (0.57) | ARDRD2DRD4ADCY6ADCY3 | |
| SCHEMBL93915 | 0.82 | DRD2 (0.57) | ARDRD2DRD4ADCY6ADCY3 | |
| Bromide SCHEMBL9538653 | 0.81 | DRD2 (0.55) | DRD2DRD4ADCY6ADCY3ADCY9 | |
| Bromide SCHEMBL4622023 | 0.81 | DRD2 (0.55) | DRD2DRD4ADCY6ADCY3ADCY9 | |
| Hydrochloric Acid SCHEMBL7571627 | 0.81 | DRD2 (0.55) | DRD2DRD4ADCY6ADCY3ADCY9 | |
| Bromide SCHEMBL29661592 | 0.81 | DRD2 (0.55) | DRD2DRD4ADCY6ADCY3ADCY9 | |
| SCHEMBL19410987 | 0.80 | AR (0.51) | ARDRD2DRD4P4HBPARP1 | |
| SCHEMBL6186362 | 0.79 | AR (0.51) | ARDRD2DRD4PARP1PARP10 | |
| SCHEMBL7078973 | 0.77 | AR (0.49) | ARDRD2DRD4PARP1PARP10 | |
| SCHEMBL7080334 | 0.76 | HTR2A (0.55) | ARDRD2DRD4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012163898-A1 | DYE COMPOSITION USING A (HYDROXY)INDOLINE COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESS AND DEVICES | L'OREAL (FR) | 2012-12-06 | — | — | WO | disclosed |
| CN-1147485-C | Indoline derivatives useful as 5-HT-2C receptor antagonists | ʷ��˿�������ȳ�ķ����˾ | 2004-04-28 | — | — | CN | disclosed |
| EP-0912554-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2002-11-27 | — | — | EP | disclosed |
| US-6369060-B1 | CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY; 5-METHYL-6-TRIFLUOROMETHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY)-PYRIDIN-3-YL CARBAMOYL)INDOLINE AND 5-METHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY) -PYRIDAZIN-3-YLCARBAMOYL)-6-TRIFLUOROMETHYLINDOLINE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-09 | — | — | US | disclosed |
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2002-03-21 | — | — | US | disclosed |
| US-6313145-B1 | FOR THERAPY OF ANXIETY AND/OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-06 | — | — | US | disclosed |
| EP-0912556-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-04 | — | — | EP | disclosed |
| EP-0984956-A1 | INDOLINE DERIVATIVES AS 5HT2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-15 | — | — | EP | disclosed |
| EP-0936924-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT 2C? ANTAGONIST AND A D 2? ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1999-08-25 | — | — | EP | disclosed |
| CN-1222152-A | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-07-07 | — | — | CN | disclosed |
| EP-0912554-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998052943-A1 | INDOLINE DERIVATIVES AS 5HT2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998004289-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT2C ANTAGONIST AND A D2 ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1998-02-05 | — | — | WO | disclosed |
| WO-1997048699-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | HTR2C, HTR1A, HTR1D | AR 491/4885DRD2 20/4885DRD4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.